Accordingly, some authors consider that a high density in B cells is characteristic for non-metastatic melanoma, being associated with a better prognosis, while others found that melanoma cells produce fibroblast growth factor-2 (FGF-2) which stimulates B cells to produce insulin-like growth factor-1 (IGF-1), exhibiting a potential resistance to BRAF and MEK inhibitors [145,146]. The gene discussed is BRAF; the disease is melanoma.